Dr Clarke will take up her role on 16 October 2018.
Dr Sarah Clarke is a consultant interventional cardiologist at Royal Papworth Hospital, Cambridge and has recently finished her 3 year tenure as President of the British Cardiovascular Society (2015–18).
Dr Clarke’s previous roles mean she will bring a breadth of managerial, cardiology and NHS experience to the BHF, having held strategic leadership positions on a regional, national and international level.
Dr Clarke is also an elected member of the European Society of Cardiology and holds several leadership roles at the American College of Cardiology. In March 2018, she was awarded the prestigious ACC International Service Award for her dedication and passion to the college.
Dr Doug Gurr, our Chairman, said: “We’re excited to welcome Dr Sarah Clarke to the Board. Her vast experience in both cardiology and senior leadership roles mean she will be invaluable in helping the BHF build on its position as the UK’s leading funder of cardiovascular research. She will also play a valuable role in helping the charity turn these research breakthroughs in to improvements in care for patients.”
Sir Kent Woods, our Deputy Chair, and Senior Medical Trustee, said: “Despite huge progress over the last 30 years, heart and circulatory diseases are still responsible for around a quarter of all deaths in the UK. Dr Clarke’s experience as a cardiologist and from the frontline of the NHS will be vital for the BHF to continue to expand its world-leading research programme and build stronger relationships with the health service. This will help ensure the benefits of our research reach patients in the shortest possible time.”
Dr Sarah Clarke said: “I am delighted to be joining the BHF’s Board at this exciting time in the charity’s journey. From my experience as a cardiologist, I’ve seen first-hand the huge impact BHF research has had in improving the prevention, diagnosis and treatment of all heart and circulatory diseases.
However, with seven million people still living with these conditions, I also know how big a challenge we face in turning promising research in to new treatments that could help save more lives. I hope my experience within the NHS and at the forefront of UK cardiology can help the BHF achieve this.”
We are the UK’s largest funder of cardiovascular research, thanks to the donations and custom of our many supporters. Between 2015 and 2020 we aim to fund more than £500 million of research that could save and improve the lives of millions of people living with heart and circulatory disease in the UK, and worldwide.
For more information, visit: www.bhf.org.uk